Foundayo pill lowers heart attack, stroke risk: Eli Lilly
- 17-Apr-2026
Eli Lilly said on Thursday its newly approved obesity pill was not inferior to a widely used long-acting insulin at lowering the risk of major heart problems in patients with type 2 diabetes and obesity. The U.S. Food and Drug Administration approved the pill, Foundayo, for weight loss earlier this month, intensifying Lilly’s competition with […]
Amazon to stock Foundayo, offer same-day delivery
- 09-Apr-2026
Amazon.com said on Thursday its pharmacy unit will stock Eli Lilly’s new weight-loss pill at kiosks located at some of the company’s primary care clinics and offer same-day delivery of the drug. Amazon Pharmacy began delivering GLP-1 medications in 2021, but does not stock injectable versions of the drugs in kiosks because they need to […]
Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly
- 29-Mar-2026
Generative-AI drug developer Insilico Medicine said on Sunday it has agreed a global licensing and research deal with U.S. drugmaker Eli Lilly that could be worth up to $2.75 billion, including milestone payments. Pharmaceutical companies are increasingly turning to AI to accelerate R&D, betting on new modelling tools and automated labs to unlock efficiency gains […]
Zepbound: Weight loss from drug reversed after stopping treatment
- 12-Dec-2023
Patients on Eli Lilly’s weight-loss drug Zepbound substantially regained weight nearly a year after stopping treatment, according to full results of a study published on Monday. The data, published in the journal JAMA, showed patients who were obese and without diabetes experienced a 14% weight regain nearly a year after they switched to a placebo […]
Zepbound: Eli Lilly obesity drug now available in pharmacies
- 06-Dec-2023
Eli Lilly on Tuesday said its recently approved obesity treatment Zepbound is now available in US pharmacies and could cost $550 a month for customers whose health insurance does not cover the drug, or half the list price. Zepbound is the latest entrant to the fast-growing market for weight-loss drugs, which is forecast to grow […]
Omvoh: Bowel disease drug gets US FDA approval
- 27-Oct-2023
Eli Lilly and Co said on Thursday that the U.S. health regulator had approved Omvoh, its drug for treating adults with moderate-to-severe active ulcerative colitis, a type of chronic inflammatory bowel disease. The drug, which will be available in the United States in coming weeks and sold under brand name Omvoh, is among Lilly’s potential […]
Drug slows Alzheimer’s progression by 35% in trial
- 03-May-2023
An experimental Alzheimer’s drug developed by Eli Lilly slowed cognitive decline by 35% in a closely watched late-stage trial, the company said on Wednesday, raising hopes for a second effective treatment for the brain-wasting disease. Eli Lilly’s shares opened at a record high of $415 on Wednesday, and were up 4.2% at $421.01 in early […]
This combo therapy cuts illness and death rate in COVID-19 patients
- 10-Mar-2021
It is the second large, late-stage study to show that combination therapy of two antibodies, bamlanivimab and etesevimab
Study shows Apple devices could identify dementia
- 08-Aug-2019
The study, tested in 113 participants over the age of 60, was conducted by Apple along with Eli Lilly and Evidation Health